See more : SPARC ELECTREX LIMITED (SPAR.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Compugen Ltd. (CGEN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Compugen Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Emova Group SA (ALEMV.PA) Income Statement Analysis – Financial Results
- Albaraka Türk Katilim Bankasi A.S. (ALBRK.IS) Income Statement Analysis – Financial Results
- Affluent Medical SA (AFME.PA) Income Statement Analysis – Financial Results
- Tong Ren Tang Technologies Co. Ltd. (1666.HK) Income Statement Analysis – Financial Results
- The Allstate Corporation (ALL-PJ) Income Statement Analysis – Financial Results
Compugen Ltd. (CGEN)
About Compugen Ltd.
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I clinical study in patients with advanced malignancies as a monotherapy; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with solid tumors; and AZD2936, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase I/II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused primarily on myeloid targets. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.46M | 7.50M | 6.00M | 2.00M | 0.00 | 17.80M | 0.00 | 712.00K | 9.28M | 12.37M | 3.55M | 242.00K | -424.00K | 1.12M | 250.00K | 338.00K | 180.00K | 215.00K | 646.00K | 4.03M | 8.83M | 11.10M | 11.36M | 6.89M | 3.24M |
| Cost of Revenue | 2.00M | 975.00K | 680.00K | 60.00K | 989.00K | 1.03M | 1.59M | 223.00K | 1.63M | 3.34M | 2.51M | 201.00K | 424.00K | 224.00K | 0.00 | 7.00K | 0.00 | 6.00K | 148.00K | 1.10M | 2.28M | 2.82M | 3.46M | 478.00K | -769.00K |
| Gross Profit | 31.46M | 6.53M | 5.32M | 1.94M | -989.00K | 16.77M | -1.59M | 489.00K | 7.64M | 9.02M | 1.04M | 41.00K | -848.00K | 891.00K | 250.00K | 331.00K | 180.00K | 209.00K | 498.00K | 2.93M | 6.55M | 8.28M | 7.91M | 6.41M | 4.01M |
| Gross Profit Ratio | 94.01% | 87.00% | 88.67% | 97.00% | 0.00% | 94.19% | 0.00% | 68.68% | 82.40% | 72.96% | 29.30% | 16.94% | 200.00% | 79.91% | 100.00% | 97.93% | 100.00% | 97.21% | 77.09% | 72.68% | 74.22% | 74.60% | 69.59% | 93.06% | 123.76% |
| Research & Development | 34.47M | 30.65M | 28.69M | 22.76M | 19.82M | 30.32M | 28.58M | 24.55M | 21.25M | 15.07M | 12.28M | 9.44M | 6.78M | 5.23M | 5.05M | 8.75M | 8.39M | 9.81M | 10.47M | 12.32M | 13.31M | 14.17M | 15.98M | 12.17M | 6.68M |
| General & Administrative | 9.73M | 10.32M | 10.86M | 9.81M | 8.41M | 8.04M | 7.63M | 7.35M | 6.01M | 5.45M | 4.85M | 3.46M | 4.59M | 2.91M | 2.15M | 3.50M | 0.00 | 0.00 | 0.00 | 3.61M | 4.38M | 5.40M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 244.00K | 932.00K | 842.00K | 871.00K | 651.00K | 1.63M | 1.19M | 1.17M | 1.31M | 838.00K | 962.00K | 684.00K | 610.00K | 633.00K | 681.00K | 996.00K | 0.00 | 0.00 | 0.00 | 5.54M | 6.57M | 3.78M | 0.00 | 0.00 | 0.00 |
| SG&A | 9.98M | 11.25M | 11.70M | 10.68M | 9.06M | 9.68M | 8.82M | 8.52M | 7.32M | 6.29M | 5.81M | 4.14M | 5.20M | 3.54M | 2.83M | 4.50M | 4.25M | 4.39M | 4.91M | 6.19M | 7.46M | 9.15M | 10.95M | 9.18M | 4.32M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -523.00K | -811.00K | -588.00K | 281.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.82M | 18.44M | 13.89M | 0.00 | 0.00 | 1.86M |
| Operating Expenses | 44.45M | 41.90M | 40.39M | 33.44M | 28.88M | 39.99M | 37.41M | 33.07M | 28.56M | 21.36M | 18.08M | 13.58M | 11.98M | 8.77M | 7.88M | 13.24M | 12.64M | 14.20M | 15.38M | 18.50M | 20.77M | 23.32M | 26.92M | 21.35M | 12.85M |
| Cost & Expenses | 46.45M | 42.87M | 41.07M | 33.50M | 28.88M | 41.03M | 37.41M | 33.30M | 30.20M | 24.70M | 20.59M | 13.78M | 11.98M | 8.99M | 7.88M | 13.25M | 12.64M | 14.21M | 15.52M | 19.60M | 23.04M | 26.14M | 30.38M | 21.83M | 12.09M |
| Interest Income | 3.24M | 1.74M | 894.00K | 1.77M | 935.00K | 643.00K | 523.00K | 728.00K | 815.00K | 346.00K | 169.00K | 301.00K | 0.00 | 0.00 | 0.00 | 502.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 31.00K | 27.00K | 25.00K | 42.00K | 32.00K | 620.00K | 508.00K | 705.00K | 755.00K | 330.00K | 141.00K | 240.00K | -306.00K | 241.00K | 65.00K | 154.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 476.00K | 482.00K | 461.00K | 715.00K | 989.00K | 1.39M | 1.59M | 1.48M | 1.11M | 658.00K | 370.00K | 299.00K | 179.00K | 201.00K | 264.00K | 477.00K | 633.00K | 996.00K | 2.39M | 1.76M | 2.68M | 2.90M | 4.28M | 4.99M | 1.86M |
| EBITDA | -12.52M | -35.37M | -34.61M | -31.50M | -27.04M | -21.83M | -35.46M | -31.10M | -19.81M | -12.34M | -17.04M | -13.27M | -11.81M | -7.68M | -7.37M | -12.03M | -11.83M | -13.08M | -12.49M | -13.81M | -12.20M | -12.15M | -14.74M | -9.94M | -6.99M |
| EBITDA Ratio | -37.41% | -471.65% | -584.57% | -1,574.80% | 0.00% | -130.49% | 0.00% | -4,576.26% | -225.48% | -99.76% | -480.22% | -5,595.87% | 2,891.51% | -767.09% | -4,566.00% | -3,835.80% | -6,578.33% | -6,095.81% | -1,967.49% | -353.89% | -138.26% | -109.45% | -126.73% | -145.13% | -215.32% |
| Operating Income | -12.99M | -35.37M | -35.07M | -31.50M | -28.88M | -23.23M | -37.41M | -32.58M | -20.92M | -12.34M | -17.04M | -13.54M | -11.98M | -7.88M | -7.63M | -12.91M | -12.46M | -13.99M | -14.88M | -15.58M | -14.22M | -15.04M | -19.02M | -16.18M | -8.85M |
| Operating Income Ratio | -38.83% | -471.65% | -584.57% | -1,574.80% | 0.00% | -130.49% | 0.00% | -4,576.26% | -225.48% | -99.76% | -480.22% | -5,595.87% | 2,825.24% | -706.55% | -3,051.60% | -3,820.12% | -6,922.22% | -6,508.37% | -2,303.10% | -386.81% | -161.07% | -135.57% | -167.42% | -234.74% | -273.34% |
| Total Other Income/Expenses | 3.21M | 1.74M | 871.00K | 1.80M | 820.00K | 628.00K | 339.00K | 1.10M | 1.15M | 1.76M | 3.46M | -86.00K | 0.00 | 675.00K | 3.79M | 401.00K | 1.00M | 1.94M | 900.00K | 1.86M | 2.77M | 2.84M | -348.00K | 1.30M | -18.00K |
| Income Before Tax | -9.78M | -33.64M | -34.20M | -29.70M | -28.06M | -22.60M | -37.07M | -31.49M | -19.77M | -10.73M | -13.58M | -13.63M | -12.00M | -7.44M | -3.84M | -12.51M | -11.46M | -13.88M | -14.66M | -15.14M | -13.55M | -13.40M | -19.37M | -14.87M | -8.87M |
| Income Before Tax Ratio | -29.24% | -448.48% | -570.05% | -1,484.90% | 0.00% | -126.96% | 0.00% | -4,422.19% | -213.14% | -86.80% | -382.73% | -5,631.40% | 2,831.13% | -667.62% | -1,537.20% | -3,701.48% | -6,365.56% | -6,457.67% | -2,269.35% | -375.94% | -153.57% | -120.79% | -170.48% | -215.85% | -273.90% |
| Income Tax Expense | 8.97M | 58.00K | -1.33M | -2.44M | -722.00K | -1.26M | -678.00K | 20.00K | 390.00K | 360.00K | 500.00K | -416.00K | 331.00K | -1.35M | -7.58M | -37.00K | 32.00K | -1.08M | -1.12M | -2.29M | -3.44M | -2.84M | -3.53M | -1.59M | -701.00K |
| Net Income | -18.75M | -33.69M | -32.87M | -27.26M | -27.34M | -22.60M | -37.07M | -31.51M | -20.16M | -11.09M | -14.08M | -13.63M | -12.00M | -7.20M | -3.83M | -12.53M | -12.11M | -13.02M | -13.98M | -13.72M | -11.44M | -12.20M | -15.14M | -13.40M | -8.13M |
| Net Income Ratio | -56.05% | -449.25% | -547.88% | -1,363.00% | 0.00% | -126.96% | 0.00% | -4,425.00% | -217.34% | -89.71% | -396.82% | -5,631.40% | 2,831.13% | -646.01% | -1,532.40% | -3,706.21% | -6,730.00% | -6,055.81% | -2,163.78% | -340.75% | -129.64% | -109.98% | -133.31% | -194.51% | -251.13% |
| EPS | -0.21 | -0.39 | -0.39 | -0.34 | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.23 | -0.36 | -0.38 | -0.35 | -0.22 | -0.13 | -0.44 | -0.43 | -0.47 | -0.50 | -0.50 | -0.43 | -0.47 | -0.58 | -0.96 | -0.58 |
| EPS Diluted | -0.21 | -0.39 | -0.39 | -0.34 | -0.43 | -0.41 | -0.72 | -0.62 | -0.40 | -0.23 | -0.36 | -0.38 | -0.35 | -0.22 | -0.13 | -0.44 | -0.43 | -0.47 | -0.50 | -0.50 | -0.43 | -0.47 | -0.58 | -0.96 | -0.58 |
| Weighted Avg Shares Out | 87.63M | 86.56M | 84.20M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 47.81M | 38.87M | 35.84M | 34.28M | 33.28M | 28.61M | 28.43M | 28.27M | 27.99M | 27.77M | 27.47M | 26.41M | 26.10M | 26.01M | 13.91M | 14.10M |
| Weighted Avg Shares Out (Dil) | 87.63M | 86.56M | 84.20M | 79.59M | 63.64M | 55.28M | 51.18M | 50.86M | 50.44M | 48.39M | 38.87M | 36.25M | 34.28M | 33.28M | 28.61M | 28.43M | 28.27M | 27.99M | 27.77M | 27.47M | 26.41M | 26.10M | 26.01M | 13.91M | 14.10M |
Compugen to Present at Single Cell Genomics 2024 Conference
HOLON, Israel , Sept. 9, 2024 /PRNewswire/ -- Compugen Ltd.
Compugen to Present at the H.C. Wainwright 26th Annual Global Investment Conference
HOLON, Israel , Aug. 29, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that management will present virtually at the H.C.
Can Compugen (CGEN) Run Higher on Rising Earnings Estimates?
Compugen (CGEN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Compugen Ltd. (CGEN) Q2 2024 Earnings Call Transcript
Compugen Ltd. (NASDAQ:CGEN ) Q2 2024 Earnings Conference Call August 6, 2024 8:30 AM ET Company Participants Yvonne Naughton - Head of Investor Relations and Corporate Communications Anat Cohen-Dayag - President and Chief Executive Officer Alberto Sessa - Chief Financial...
Compugen (CGEN) Reports Q2 Loss, Tops Revenue Estimates
Compugen (CGEN) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.11 per share a year ago.
Compugen Reports Second Quarter 2024 Results
FDA clearance of COM503 IND in July 2024 triggered a $30 million milestone payment from Gilead On track to present data from COM701 + COM902 + pembrolizumab, platinum resistant ovarian cancer study in Q4 2024 Partner, AstraZeneca, advanced development of rilvegostomig, and provided...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harness cytokine biology for cancer therapeutics as monotherapy and in combination in advanced solid tumors...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024
HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that the Company will release its second quarter 2024 financial results on Tuesday, August...
Compugen to Present at Upcoming Antibody Industrial Symposium
HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today announced that Pierre Ferré, Ph.D, SVP, Preclinical Development and Corporate Operations, Compugen will present a...
Compugen (CGEN) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for Compugen (CGEN), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the...
Source: https://incomestatements.info
Category: Stock Reports